Immuntherapie mit Checkpointinhibitoren und schilddrüsentypische Komplikationen

Zusammenfassung

Die Therapie mit Immuncheckpointinhibitoren findet in den letzten Jahren zunehmend Anwendung bei der Therapie einer Vielzahl onkologischer Erkrankungen. Schilddrüsenfunktionsstörungen stellen eine der häufigsten unerwünschten Nebenwirkungen unter diesen Therapien dar. Initial kommt es häufig zu einer transienten, zerfallsbedingten Hyperthyreose, die dann in eine Hypothyreose übergeht. Der genaue pathophysiologische Mechanismus ist jedoch noch nicht hinreichend geklärt. Die Verläufe können asymptomatisch sein; nicht selten kommt es jedoch zu hyper- und hypothyreosetypischen Symptomen, die unter Umständen erst spät einer Schilddrüsenfunktionsstörung zugeordnet werden, da diese letztlich unspezifisch und auch im Rahmen der onkologischen Grunderkrankung denkbar sind. Daher ist bei Verdacht auf das Vorliegen eine fachspezifische Vorstellung beim Nuklearmediziner wichtig zur gezielten Diagnostik mittels Anamnese, Labor, Sonografie und ggf. auch Szintigrafie um weitere Differenzialdiagnosen auszuschließen. Bei Auftreten einer Hyperthyreose steht die symptomatische Therapie im Vordergrund; der Einsatz von Thyreostatika ist nur eingeschränkt zu empfehlen. Eine Hypothyreose sollte mit einer an den TSH-Wert und die Klinik angepassten Schilddrüsenhormonsubstitution therapiert werden. Bis ein stabiler Zustand erreicht ist, sollten dem Krankheitsverlauf angepasste fachspezifische Vorstellungen erfolgen. Im Regelfall kann die Immuntherapie ohne Unterbrechung fortgeführt werden.

Abstract

Therapy with immune checkpoint inhibitors has been increasingly used in recent years for many different tumor entities. Thyroid dysfunction is one of the most common adverse effects of these therapies. Initially, transient, decay-related hyperthyroidism often occurs, which then progresses to hypothyroidism. However, the exact pathophysiological mechanism is not yet sufficiently clarified. Courses can be asymptomatic. However, it is not uncommon for typical symptoms of hyperthyroidism and hypothyroidism to appear, which possibly can only be attributed to a thyroid dysfunction at a late stage, since these are at last non-specific and also conceivable in the context of the oncological underlying disease. Therefore, if there is a suspicion of the presence, the consultation of a nuclear medicine doctor is important for targeted diagnostics using anamnesis, laboratory, sonography and, if necessary, also scintigraphy in order to rule out further differential diagnoses. If hyperthyroidism occurs, the focus is on symptomatic therapy; the use of antithyroid drugs is only recommended to a limited extent. Hypothyroidism should be treated with thyroid hormone substitution adapted to the TSH value and the clinical condition. Until a stable condition is reached, subject-specific presentations adapted to the course of the disease should be made. Usually the immunotherapy can be continued without interruption.

Schlüsselwörter

Checkpoint-Inhibitoren - Immune-related adverse effects - Schilddrüsenfunktionsstörungen - Autoimmunthyreoiditis

Keywords

Checkpoint inhibitors - immune-related adverse effects - thyroid dysfunction - autoimmune thyroiditis

Publikationsverlauf

Artikel online veröffentlicht:
01. März 2024

• Literatur

• 1 Ramos-Casals M, Brahmer JR, Callahan MK. et al. Immune-related adverse events of checkpoint inhibitors. Nat Rev Dis Primers 2020; 6: 38 DOI: 10.1038/s41572-020-0160-6.
• 2 Xu C, Chen Y-P, Du X-J. et al. Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysis. BMJ 2018; 363: k4226 DOI: 10.1136/bmj.k4226.
• 3 Haanen JBAG, Carbonnel F, Robert C. et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2017; 28: iv119-iv142 DOI: 10.1093/annonc/mdx225.
• 4 Arnaud-Coffin P, Maillet D, Gan HK. et al. A systematic review of adverse events in randomized trials assessing immune checkpoint inhibitors. Int J Cancer 2019; 145: 639-648 DOI: 10.1002/ijc.32132.
• 5 Muir CA, Clifton-Bligh RJ, Long GV. et al. Thyroid Immune-related Adverse Events Following Immune Checkpoint Inhibitor Treatment. J Clin Endocrinol Metab 2021; 106: e3704-e3713 DOI: 10.1210/clinem/dgab263.
• 6 Itzstein MS von, Gonugunta AS, Wang Y. et al. Correction to: Divergent prognostic effects of pre-existing and treatment-emergent thyroid dysfunction in patients treated with immune checkpoint inhibitors. Cancer Immunol Immunother 2022; 71: 2183-2184 DOI: 10.1007/s00262-022-03218-0..
• 7 Chang L-S, Barroso-Sousa R, Tolaney SM. et al. Endocrine Toxicity of Cancer Immunotherapy Targeting Immune Checkpoints. Endocr Rev 2019; 40: 17-65 DOI: 10.1210/er.2018-00006.
• 8 Barroso-Sousa R, Barry WT, Garrido-Castro AC. et al. Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-analysis. JAMA Oncol 2018; 4: 173-182 DOI: 10.1001/jamaoncol.2017.3064.
• 9 Muir CA, Menzies AM, Clifton-Bligh R. et al. Thyroid Toxicity Following Immune Checkpoint Inhibitor Treatment in Advanced Cancer. Thyroid 2020; 30: 1458-1469 DOI: 10.1089/thy.2020.0032.
• 10 Iyer PC, Cabanillas ME, Waguespack SG. et al. Immune-Related Thyroiditis with Immune Checkpoint Inhibitors. Thyroid 2018; 28: 1243-1251 DOI: 10.1089/thy.2018.0116.
• 11 Angell TE, Le Min, Wieczorek TJ. et al. Unique Cytologic Features of Thyroiditis Caused by Immune Checkpoint Inhibitor Therapy for Malignant Melanoma. Genes Dis 2018; 5: 46-48 DOI: 10.1016/j.gendis.2017.11.002.
• 12 Filette J de, Jansen Y, Schreuer M. et al. Incidence of Thyroid-Related Adverse Events in Melanoma Patients Treated With Pembrolizumab. J Clin Endocrinol Metab 2016; 101: 4431-4439 DOI: 10.1210/jc.2016-2300.
• 13 Peiró I, Palmero R, Iglesias P. et al. Thyroid dysfunction induced by nivolumab: searching for disease patterns and outcomes. Endocrine 2019; 64: 605-613 DOI: 10.1007/s12020-019-01871-7.
• 14 Lozano AX, Chaudhuri AA, Nene A. et al. T cell characteristics associated with toxicity to immune checkpoint blockade in patients with melanoma. Nat Med 2022; 28: 353-362 DOI: 10.1038/s41591-021-01623-z.
• 15 Delivanis DA, Gustafson MP, Bornschlegl S. et al. Pembrolizumab-Induced Thyroiditis: Comprehensive Clinical Review and Insights Into Underlying Involved Mechanisms. J Clin Endocrinol Metab 2017; 102: 2770-2780 DOI: 10.1210/jc.2017-00448.
• 16 Yamauchi I, Sakane Y, Fukuda Y. et al. Clinical Features of Nivolumab-Induced Thyroiditis: A Case Series Study. Thyroid 2017; 27: 894-901 DOI: 10.1089/thy.2016.0562.
• 17 Osorio JC, Ni A, Chaft JE. et al. Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer. Ann Oncol 2017; 28: 583-589 DOI: 10.1093/annonc/mdw640.
• 18 Kobayashi T, Iwama S, Yasuda Y. et al. Patients With Antithyroid Antibodies Are Prone To Develop Destructive Thyroiditis by Nivolumab: A Prospective Study. J Endocr Soc 2018; 2: 241-251 DOI: 10.1210/js.2017-00432.
• 19 Yuen KCJ, Samson SL, Bancos I. et al. American Association of Clinical Endocrinology Disease State Clinical Review: Evaluation and Management of Immune Checkpoint Inhibitor-Mediated Endocrinopathies: A Practical Case-Based Clinical Approach. Endocr Pract 2022; 28: 719-731 DOI: 10.1016/j.eprac.2022.04.010.
• 20 Ross DS, Burch HB, Cooper DS. et al. 2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis. Thyroid 2016; 26: 1343-1421 DOI: 10.1089/thy.2016.0229.
• 21 Byun DJ, Wolchok JD, Rosenberg LM. et al. Cancer immunotherapy – immune checkpoint blockade and associated endocrinopathies. Nat Rev Endocrinol 2017; 13: 195-207 DOI: 10.1038/nrendo.2016.205.
• 22 Illouz F, Drui D, Caron P. et al. Expert opinion on thyroid complications in immunotherapy. Ann Endocrinol (Paris) 2018; 79: 555-561 DOI: 10.1016/j.ando.2018.07.007.
• 23 Puzanov I, Diab A, Abdallah K. et al. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. J Immunother Cancer 2017; 5: 95 DOI: 10.1186/s40425-017-0300-z.
• 24 Astwood EB, Vanderlaan WP. Treatment of hyperthyroidism with propylthiouracil. Ann Intern Med 1946; 25: 813-821 DOI: 10.7326/0003-4819-25-5-813.
• 25 Zhou T, Mahn R, Möhring C. et al. Case Report: Sustained complete remission on combination therapy with olaparib and pembrolizumab in BRCA2-mutated and PD-L1-positive metastatic cholangiocarcinoma after platinum derivate. Front Oncol 2022; 12: 933943 DOI: 10.3389/fonc.2022.933943.
• 26 Haanen J, Obeid M, Spain L. et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol 2022; 33: 1217-1238 DOI: 10.1016/j.annonc.2022.10.00.